Pharma Group, Under Pressure, Punches Back on Prices

  • Industry responds to candidates’ plans, congressional scrutiny
  • Strategies include showing the high cost of drug failures

A top pharmaceutical lobbying group will begin a counteroffensive against scrutiny of industry pricing practices, responding to criticism from both major U.S. political parties in a contentious presidential election season.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.